COVID-19 test developer Co-Diagnostics (CODX ) is poised to finish the day solidly in the green on higher volume, enjoying a surge in buying in the wake of reported disappointing sensitivity data from a New York study evaluating Abbott's ID Now rapid molecular test for SARS-CoV-2.
https://www.investing.com/equities/co-diagnostics
https://www.investing.com/equities/co-diagnostics